01 · ВведениеПатент как корпоративный актив
Патент — это юридически защищённое право монопольно использовать изобретение в течение 20 лет от даты подачи заявки. Для компании, владеющей portfolio патентов, эта защита часто составляет основную часть enterprise value — особенно в pharmaceutical, biotech, semiconductors, advanced materials и mechanical engineering. Когда ваш бизнес стоит на патентах, вопрос «где они должны жить?» — стратегический.
Cayman Islands не являются местом регистрации патентов в традиционном смысле — patents выдаются national patent offices (USPTO в США, EPO в Европе, JPO в Японии и т. д.). Но Cayman entity может быть beneficial owner этих национальных патентов через recordal of ownership в каждом patent registry. Один Cayman holding company может owning portfolio из 50, 200 или даже 2000+ патентов across multiple jurisdictions.
Cayman patent holding — это не самая популярная structure (Singapore, Switzerland, Ireland более распространены для pharma/biotech), но в специфических scenarios — single-asset structures, exit-oriented companies, structures с patents derived from non-US R&D — Cayman даёт уникальное сочетание налоговой нейтральности, BEPS-compliance возможностей и institutional reputation.
Patent holdings — это long-term game. Patents имеют 20-летний life, royalty streams растягиваются на decades, и structure decisions made today affect company economics на 10-15 лет вперёд. Wrong jurisdiction choice — это очень expensive mistake.
Главная особенность patent holdings
В отличие от software или brands, patents имеют strict regulatory framework в каждой национальной юрисдикции. USPTO, EPO, и другие patent offices имеют свои правила recordal изменений ownership, требования maintenance fees, deadlines для prosecution actions. Cayman entity должна activate management этого framework — а не пассивно «владеть» через paperwork.
02 · Правовая базаPatents в международном корпоративном контексте
Patents регулируются national laws — нет такого понятия как «international patent» (даже PCT international applications в конечном счёте проходят через national phases). Поэтому Cayman patent holding оперирует в multi-layered legal framework:
2.1. Cayman entity layer
- Companies Act (2023 Revision) или Limited Liability Companies Act — корпоративная правоспособность entity
- Tax Concessions Act — гарантия налоговой нейтральности до 50 лет
- International Tax Co-operation (Economic Substance) Act — IP business как relevant activity с DEMPE requirements
- Beneficial Ownership Transparency Act 2023 — UBO disclosure для regulators
2.2. National patent law layer
Каждый патент существует в своей jurisdiction:
- США (35 USC, regulated by USPTO) — самые ценные patents для большинства technology companies. Strict requirements для recordal изменений ownership (37 CFR 3.71-3.85). Maintenance fees каждые 4-8-12 лет. Strict deadline rules — missed deadline = patent loss.
- European Patent Convention (EPC) — единая европейская процедура через EPO до granting, после — национальные patents в выбранных странах. Nationaland patent offices (DPMA Germany, INPI France, etc.) handle ownership recordal post-grant.
- Patent Cooperation Treaty (PCT) — international application giving 30 months breathing room before national phase. Cayman entity может быть applicant в PCT applications.
- National laws других major jurisdictions — Japan (JPO), China (CNIPA), Korea (KIPO), India (IPO), Brazil (INPI), Australia (IP Australia)
2.3. International tax framework layer
- OECD Transfer Pricing Guidelines — DEMPE analysis для royalty transactions с related parties
- BEPS Action 5 — substantial activity requirements для IP regimes
- Country-by-Country Reporting (для groups с consolidated revenue €750M+)
- DAC6 / Mandatory Disclosure Rules — reporting cross-border arrangements в EU
- Tax treaties — withholding tax rates на royalty payments между different jurisdictions
В одном из наших pharma cases приходилось координировать ownership records для одного patent в 14 разных jurisdictions — каждая со своими formal requirements, language requirements (Japan требует Japanese-language documents), notarisation requirements, fee structures. Это не «оформить ownership» — это complex multi-jurisdictional project.
— Партнёр-юрист, специалист по IP structures03 · Recordal ownershipКак Cayman entity «владеет» national patents
3.1. Базовый principle: chain of title
National patent registry tracks chain of title — последовательность ownership transfers с момента issuance до current owner. Чтобы Cayman entity была «owner» US patent, нужно:
- Original assignment — inventor(s) assign rights to company (часто employer through employment agreement)
- Transfer assignment — original company assigns rights to Cayman entity (это и есть IP transfer triggering tax events)
- Recordal в USPTO — formal filing документов assignment в USPTO assignment database (через EPAS — Electronic Patent Assignment System)
- Recordal fee — currently $40 per assignment per patent (could be 100+ patents in single assignment recordation)
После recordal Cayman entity появляется в USPTO public records как owner. Все subsequent USPTO communications direct к Cayman entity (или его designated correspondent). Maintenance fees должны платиться от имени Cayman entity. Любое subsequent transfer должно быть recorded similarly.
3.2. Параллельные процедуры в других jurisdictions
Same patent в US и Europe — это actually две разные patents (USPTO patent и EPO-validated national patents). Recordal Cayman ownership должен быть completed в каждой jurisdiction separately:
- USPTO — federal recordation, applies to all US patents
- EPO post-grant — national registries — German DPMA, French INPI, UK IPO, etc. (typically 5-15 EU countries для valuable patents). Each nation requires separate filing с translated documents если local language requirements
- Asian markets — Japan, China, Korea, India — каждая со своими formal requirements
- Other markets — Brazil, Russia, Australia, Canada
Для valuable pharma patent recorded в 30+ jurisdictions, total recordation costs могут достигать $15-30k одноразово plus ongoing translation и service fees. Это часть structure cost.
3.3. Power of attorney и patent counsel
Cayman entity не может directly interact с USPTO как foreign entity без US-licensed patent attorney. Стандартная structure:
- Cayman entity engages US patent counsel (большие IP firms — Morrison & Foerster, Wilson Sonsini, Fish & Richardson, Ropes & Gray)
- Power of attorney granted to specific attorneys for filings и USPTO interactions
- Annual budget для patent maintenance ($5-50k+ для significant portfolios)
- Strategic decisions (когда file new patents, когда continue prosecution, когда litigate) made by Cayman entity board, executed by patent counsel
Same pattern repeats для каждой jurisdiction — Japanese patent attorney для JPO, Chinese patent agent для CNIPA, etc. Modern IP holdings часто use single global IP firm (e.g., Hogan Lovells, Clifford Chance) с offices in major jurisdictions for streamlined coordination.
04 · DEMPE функции для patent holdingЧто substance означает на practice
OECD DEMPE framework для IP business требует, чтобы entity, claiming royalty income, выполняла Development, Enhancement, Maintenance, Protection, и Exploitation functions. Для patent holdings это применяется specific way:
4.1. Development
Patent rights должны originate из R&D activities. Если patents acquired from third parties (acquisition or buyout), это automatically «high-risk IP business» с stricter substance requirements. Better path — Cayman entity participates в development:
- Financing R&D: Cayman entity provides funding к operating subsidiaries doing R&D, in exchange for IP ownership of results
- Strategic direction: Cayman board approves R&D priorities, allocates budget между different research streams
- Risk-bearing: Cayman entity takes financial risk of unsuccessful R&D (failure tolerance)
- Documentation: written R&D agreements, board resolutions approving funding, progress reports back to board
4.2. Enhancement
Existing patents continuously enhanced: filing continuation applications для broader claims, divisional applications для spin-off inventions, foreign filings для new markets:
- Annual patent strategy plans approved by Cayman board
- Decisions about which inventions to patent (not all R&D results worth patent costs)
- Geographic expansion decisions (filing в new markets adds $10-25k per country)
- Continuation strategy для maximize patent term and claim scope
4.3. Maintenance
Самая operational function. Each patent requires:
- Annual или periodic maintenance fees (USPTO: $1,600-7,400 per patent per period)
- Response к office actions от patent offices
- Tracking deadlines (statute of limitations, priority claims, foreign filing deadlines)
- Decisions to abandon non-valuable patents (significant cost savings)
Cayman entity должна имеет docketing system tracking all deadlines for all patents в portfolio. Modern systems (Anaqua, Computer Packages Inc, FoundationIP, IPzen) provide cloud-based tracking. Cayman entity subscribes и manages, with patent counsel executing actual filings.
4.4. Protection
Active protection крайне важна для patent holdings:
- Infringement monitoring: regular searches public databases, market surveillance
- Cease & desist letters: initial response к suspected infringement
- Litigation strategy: when to escalate, in which jurisdictions, with what objectives (damages, injunctive relief, licensing)
- Defensive considerations: counter-claims, prior art searches, validity defenses
Patent litigation — это extremely expensive (US patent case typically $3-5M в legal fees). Cayman entity must have financial capacity для protect rights. Some entities maintain dedicated patent litigation insurance ($50-200k annual premium для significant portfolio).
4.5. Exploitation
Финальная и most lucrative function — actually monetizing patents:
- Licensing strategy: which patents to license, on what terms, to which licensees
- Royalty rate setting: based on industry standards, comparable transactions, competitive analysis
- Partner due diligence: vetting potential licensees
- Active licensee management: monitoring royalty reports, audit rights, performance enforcement
- Strategic partnerships: cross-licensing, patent pools, standard-essential patent commitments
- R&D funding agreements documenting Cayman entity participation
- Annual patent portfolio strategy plan approved by board
- Docketing system tracking all patent deadlines
- Patent counsel relationships в all major jurisdictions
- Annual budget для maintenance, prosecution, litigation
- Infringement monitoring infrastructure
- Active licensing programme (если applicable)
- Comprehensive documentation всех strategic decisions
05 · 5 типичных сценариевКогда Cayman patent holding works
Single-asset biotech: protecting drug patent before exit
VC-backed biotech developed novel drug candidate, currently в Phase 2 clinical trials. Lead patent broad, covering composition of matter и multiple use cases. Expected exit through acquisition by big pharma в 24-36 months. Founders want clean asset structure для maximize acquisition value.
Solution: Cayman holding company owns lead patent + related continuations. Operating company licenses patent для conduct trials. Patent fully separated от operational liabilities (clinical trial risks, manufacturing issues, employment matters). Acquiring company can acquire patent rights в clean transaction independent of operational entity.
Outcome: typical premium of 15-20% on acquisition multiple для clean IP separation. Pharma acquisitions с clear patent ownership close 3-6 months faster чем messy structures requiring extensive due diligence on IP chain of title.
Semiconductor company: 200+ patent portfolio
Established semiconductor company с manufacturing operations in US, Taiwan, Singapore. R&D centres в US (Austin), Israel, India. Patent portfolio of 200+ patents across digital signal processing, mixed-signal design, manufacturing processes. Annual licensing revenue $25-30M from cross-licensing arrangements with major chip vendors.
Structure: Cayman patent holding owns entire patent portfolio. Operating subsidiaries hold licenses для their respective regional operations. Cross-licensing partners deal directly with Cayman entity. Strategic decisions about portfolio (acquisitions, divestments, litigation) made through Cayman board with technical advisors.
Tax savings: $5-7M annually от channeling royalty income through Cayman zero-tax regime. Substance cost approximately $400k annually. Net benefit $4.5-6.5M annually plus significantly cleaner exit potential если company eventually sold.
Pre-acquisition: prepping company for sale
Mid-cap manufacturing company expects acquisition в 18-24 months. Significant patent portfolio mostly mechanical engineering и manufacturing processes. Target buyers — large industrial conglomerates with sophisticated due diligence processes. Founders want maximum exit value и clean transaction.
Pre-exit restructuring: 18 months before expected sale, transfer patent portfolio к Cayman holding. Establish substance gradually (initially shared services с substance provider, eventually dedicated personnel). Create proper licensing structure between Cayman holding и operating subsidiaries. Document everything through DEMPE framework.
By exit time: Cayman holding has 18-month track record, substance well-established, all patents recorded with appropriate ownership. Buyer can acquire either entire group или just IP holding (преимущество если только IP wanted). Much cleaner due diligence process.
Deeptech startup: AI-related patents
Series B AI startup с novel ML algorithms protected through 15-20 patents (filed across US, EU, China). Investor base international (US, Asian, European VCs). Strategic uncertainty about где company will eventually have headquartered (depends on customer traction patterns).
Cayman holding approach: patents owned through Cayman entity allows flexible structure regardless of eventual headquarters location. If company moves to US — license patents to US operating entity. If APAC focus — license to Singapore/Hong Kong subsidiary. If exit through acquisition — IP separately transferable.
Considerations: AI patents often controversial (validity challenges in US through 35 USC 101 motions). Active protection и strategic enforcement essential. Cayman holding должна budget для potential litigation costs ($2-5M per major case).
Patent assertion entity (PAE)
Specialized entity formed для acquire patent portfolios from operating companies, enforce them through licensing programs или litigation. Sometimes called «patent trolls» (pejorative) or «non-practicing entities» (NPE).
Why Cayman: patent assertion business model concentrates massive royalty/settlement income in single entity. Cayman zero-tax regime maximizes cash flow для acquisition more patents и pursuit more cases. Bermuda alternative similar но less popular for this use case.
Critical considerations: reputational concerns (PAE business model controversial), litigation expense (each US case $3-5M), defensive aggregation moves by major companies (RPX, Unified Patents) reducing settlement leverage, recent court decisions limiting PAE damages (Supreme Court eBay case still relevant). This is specialized business model, not for typical operating company structures.
06 · Создание patent holdingЭтапы и сроки
Установление operational Cayman patent holding занимает 10-18 weeks в зависимости от portfolio complexity и количества jurisdictions. Это significantly longer чем для software или brand holdings из-за formal recordal procedures в multiple national patent offices.
Этап 1. IP audit и valuation (недели 1-3)
- Comprehensive inventory всех patents (granted, applications, abandonded)
- Verification chain of title для каждого patent (особенно critical если patents originated через acquisitions or employee inventors с complex assignment history)
- Independent valuation: comparable transactions analysis, royalty rate benchmarking, DCF projection
- Identification «family» relationships: parent applications, continuations, divisionals, foreign equivalents
- Decision о scope transfer (entire portfolio, или selected patents/families)
Этап 2. Cayman entity formation (недели 2-4)
- Standard Cayman Exempted Company или LLC formation
- Tax Exemption Certificate application
- Initial directors with technical/IP background (not just generic corporate)
- Banking introduction (might require specific patent-friendly bank в some cases)
Этап 3. Substance establishment (недели 4-12)
- Office space в Cayman (typically 250-500 sqft)
- Personnel recruitment: minimum 1-2 with IP/technical background, или substance provider with relevant capabilities
- Patent management infrastructure: docketing system subscription, patent counsel relationships
- Board governance setup: meeting calendar, decision-making processes
- R&D funding agreements с operating subsidiaries (если ongoing R&D)
Этап 4. Patent assignment и recordal (недели 8-16)
Самый длинный этап. Coordination across multiple jurisdictions:
- Master Assignment Agreement covering all patents being transferred
- Per-jurisdiction filings: USPTO recordal, EPO national validations recordal, Asian jurisdictions, others
- Translations where required (Japan, China, Korea, etc.)
- Notarisations и apostilling (some jurisdictions)
- Confirmation of recordal completion
- License-back agreements с operating subsidiaries (для continued use of patents)
Этап 5. Tax filings и operational launch (недели 14-18)
- Tax filings в jurisdictions where patents previously held (capital gains on transfer, exit taxes if applicable)
- Transfer pricing documentation (master file, local file)
- Inter-company licensing agreements activated
- First royalty invoicing
- Annual patent maintenance budget activated
07 · Экономика patent holdingРеальные затраты на срок службы конструкции
7.1. Setup costs (year 1)
- Legal preparation entity: $8 000 — 15 000
- IP audit и valuation: $20 000 — 80 000 (зависит от portfolio size и complexity)
- Patent assignment recordal (multiple jurisdictions): $15 000 — 50 000
- Translations и apostilling: $5 000 — 25 000
- Transfer pricing study: $25 000 — 80 000
- Substance establishment (office, initial personnel): $30 000 — 60 000
- Patent counsel relationships setup: $10 000 — 30 000
- Docketing system subscription и data migration: $15 000 — 50 000
Total setup: $130 000 — 390 000. Significantly higher than software/brand holdings из-за multi-jurisdictional complexity.
7.2. Annual operating costs
- Office rent и facilities: $24 000 — 60 000
- Personnel costs: $80 000 — 200 000
- Director fees: $30 000 — 80 000
- Patent counsel annual retainers (multiple jurisdictions): $40 000 — 200 000
- Patent maintenance fees (USPTO, EPO national, Asian markets): $20 000 — 200 000+ (depends portfolio size)
- Docketing system: $15 000 — 50 000
- Audit и compliance: $20 000 — 60 000
- Legal annual: $30 000 — 80 000
Annual operating: $260 000 — 950 000 / год. The number scales significantly with portfolio size — 200-patent portfolio costs 2-3x more annually чем 20-patent portfolio.
7.3. Breakeven analysis
Cayman patent holding economically оправдан когда:
- Annual royalty stream $5M+ (для 30%+ tax savings to exceed $300k+ annual cost)
- OR significant capital gains potential on patent sale (multiple millions saved on no Cayman capital gains tax)
- OR multi-jurisdictional R&D requiring centralised IP ownership for operational reasons
- OR exit-oriented company где clean IP separation добавляет value на acquisition
For smaller portfolios (less than $3M annual royalty), structure economics rarely work out. Better to keep patents в operating entity and optimize through other means (R&D tax credits, accelerated depreciation, jurisdictional choice for primary entity).
08 · Mini-кейсБиотехнологическая стадия на средней стадии с планированием перед IPO
Phase 3 biotech: structuring patent portfolio для IPO
Clinical-stage biotech с lead drug в Phase 3 trials, projected approval Q4 2025. Patent portfolio: 1 composition-of-matter patent (lead asset, $2.5B projected revenue), 4 method-of-use patents, 2 manufacturing process patents, 5 pending applications. Filed в US, EU (validated в 7 countries), Japan, Korea, Australia, Brazil.
Решение: Cayman Exempted Company как patent holder. Existing operating entity (Delaware C-corp) retained для clinical operations и future commercialization. Patent assigned to Cayman holding, license-back agreement с Delaware operating entity для continued clinical development. Substance: 2 directors with pharma/IP background, shared services agreement с Cayman substance provider, monthly virtual board meetings, quarterly in-person Cayman meetings.
Patent assignments coordinated through Hogan Lovells with simultaneous filings across 14 jurisdictions. Transfer pricing study by KPMG established arm's length royalty (8% of net sales). Tax analysis confirmed deemed sale event на transfer (US capital gains $1.2M, paid). Future royalty stream таx-neutral в Cayman.
09 · Cayman vs альтернативные jurisdictions
| Параметр | Cayman | Switzerland (Patent Box) | Ireland (KDB) | Singapore (IP Dev) |
|---|---|---|---|---|
| Effective tax rate (royalty) | 0% | ~10-12% | 6.25% | 5-10% |
| Capital gains on patent sale | 0% | Variable by canton | 33% (no relief) | 0% |
| Substance requirements | DEMPE (reasonable) | Substantial local R&D | Strict (KDB-qualifying R&D) | Substantial local R&D |
| Pharma reputation | Limited | Excellent | Strong | Growing |
| EU passporting | Нет | Нет | Да | Нет |
| Setup cost | $130-390k | $200-500k | $180-450k | $120-350k |
| Annual operating | $260-950k | $500k-1.5M | $400k-1M | $300-800k |
| Best для | Single-asset, exit-oriented, semiconductor | Pharma, swiss-derived R&D | EU pharma, EU customer base | APAC pharma, Asian R&D |
Cayman best for: single-asset biotechs with exit orientation, semiconductor/deeptech with global R&D, patent assertion entities. Switzerland and Ireland better for established pharma с substantial local R&D. Singapore optimal для APAC-focused operations.
Hybrid structures common для large pharma — Cayman for capital gains optimization on patent sales, Ireland for ongoing royalty management with EU customers, Switzerland for headquarters substance.
10 · Specific patent risksПомимо общих соображений владения интеллектуальной собственностью
10.1. Section 367(d) US Outbound Transfer Rules
For US-developed patents transferred outbound (e.g., from Delaware C-corp to Cayman holding), Section 367(d) of US Internal Revenue Code creates ongoing tax obligations even after transfer. Specifically:
- Transferring company deemed to receive «commensurate with income» royalty payments annually
- Calculation based on actual income generated by patents
- Effectively eliminates much of expected tax savings from transfer
- Applies for life of patent (up to 20 years)
This is critical consideration — many US companies discover Section 367(d) only после transfer, making structure ineffective. Pre-transfer planning must include tax counsel review specifically for Section 367(d) implications.
10.2. Patent litigation venue restrictions
Where Cayman entity sues for patent infringement matters significantly. US Supreme Court в TC Heartland (2017) restricted patent venue, requiring suit in defendant's state of incorporation или where defendant has «regular and established place of business». Cayman entity may need to coordinate with operating subsidiary для bring suit.
Some defendants challenge standing of Cayman entity as plaintiff, особенно если Cayman entity perceived as «paper» owner without actual IP management. Strong substance documentation crucial for surviving standing challenges.
10.3. Patent term considerations
Patents have 20-year terms from filing. By time Cayman holding established, patents may already be 5-10 years old. Diminishing remaining term affects valuation:
- Patent worth dramatically more in years 1-10 vs years 15-20
- Transfer pricing must reflect remaining patent life
- Long-term royalty agreements may need declining royalty rates
10.4. Standard-Essential Patents (SEP)
SEPs subject to FRAND (Fair, Reasonable, Non-Discriminatory) licensing commitments. Cayman entity owning SEPs must comply with FRAND obligations regardless of jurisdiction. EU specifically issued guidance on SEP licensing — Cayman entity not exempt from these.
Recent EU regulation (effective 2024) requires SEP holders to register patents with EUIPO and submit to mandatory mediation. Adds compliance burden для Cayman SEP holders.
10.5. Anti-trust considerations
Patent licensing programs могут trigger anti-trust scrutiny, especially:
- Patent pools combining multiple owners' patents
- Tying arrangements (must license patent A to license patent B)
- Refusal to license to certain competitors
- Excessive royalty demands (especially для FRAND commitments)
Anti-trust enforcement varies by jurisdiction — EU и US have different standards. Cayman entity activities globally subject to anti-trust laws of countries where licensing affects markets.
11 · FAQСамые частые вопросы про patent holdings
Можно ли filing новые patents directly от Cayman entity?
Yes, but rarely optimal. Patent applications need named inventors (must be natural persons doing actual inventive work). Cayman entity sits as applicant/assignee, but inventors typically employed by operating subsidiaries в R&D countries. Better practice: file initial application from country where inventors work (entitlement to local R&D credits, simpler procedure), then assign to Cayman shortly after filing. This matches «follow the inventor» principle and avoids questions about chain of title.
А как насчет патентных заявок по процедуре РСТ?
Cayman entity can be applicant in PCT international applications. PCT gives 30 months from priority date before national phase entry. This buys time for strategic decisions — file PCT claiming Cayman entity as applicant, then enter national phases в selected jurisdictions. Cost-effective approach: PCT covers 156 countries through single application, decision about specific countries deferred 30 months. Total PCT cost approximately $5-15k per application через filing к international preliminary examination.
Как это работает с сотрудниками-изобретателями?
Critical infrastructure: solid employment agreements requiring assignment of inventions to employer (operating subsidiary). Then operating subsidiary assigns to Cayman holding. Each link в chain critical — if employment agreement defective in one country, that link broken для inventions из that location. Modern structures use «automatic assignment» language plus actual assignment documents at filing time. Some countries (Germany, Japan) have specific employee inventor compensation laws requiring payments — these must be honored по local law.
Что произойдет, если организация Каймановых островов захочет подать в суд за нарушение авторских прав?
Cayman entity must hire local litigation counsel в jurisdiction of suit. US patent litigation особенно complex — must establish standing, choose proper venue (TC Heartland restrictions), navigate procedural requirements. Some jurisdictions (Germany, UK) preferred for patent litigation due to specialized courts, faster procedures. Cayman entity participates через counsel; key strategic decisions made by Cayman board. Major patent cases costly: US case averaging $3-5M in legal fees, Germany €500k-1M, UK £500k-1.5M. Insurance increasingly available для defensive coverage.
Как определяются ставки роялти?
Multiple OECD-recognised methods. Most common combinations: (1) Comparable Uncontrolled Price method using third-party patent licenses в same industry; (2) Profit Split allocating residual profits between IP owner and licensee; (3) industry-standard royalty rates (RoyaltyStat database, KtMine, ktMINE). Conservative rates: pharma 5-12% net sales, semiconductor 1-5%, software 5-15%, mechanical/industrial 2-6%. Big-4 firms provide benchmarking studies ($25-80k for comprehensive analysis). Conservative position favours lower royalty rate within arm's length range — this is preferable to aggressive rate that gets challenged and adjusted downward с penalties.
А как насчет ожидающих рассмотрения патентных заявок?
Pending applications can be transferred to Cayman entity same as granted patents. Some considerations: «provisional» applications в US (temporary filings before regular application) typically not transferred until conversion to non-provisional. Patent applications have inherent value uncertainty — may or may not grant, claims may be narrowed during prosecution. Valuation accordingly conservative. Once granted, retroactive licensing agreements typical для backdate royalty obligations to grant date.
Существуют ли специальные правила для биотехнологических/фармацевтических патентов?
Yes, several considerations. (1) Patent term restoration available для drugs requiring lengthy regulatory approval (US Hatch-Waxman, EU SPC) — adds up to 5 years patent life, considerable value. Cayman entity must apply for these в each jurisdiction. (2) Orange Book listings (US) для FDA-approved drugs trigger special considerations for licensing transfers. (3) Bolar exemptions allow generic manufacturers preparation activities before patent expiry — affects timing of revenue projections. Specialized pharma counsel essential during structure design.
12 · ЗаключениеКогда Cayman patent holding makes sense
Cayman patent holdings — это specialized structures для specific scenarios. Не universal solution для all IP businesses, но для правильных cases — efficient and effective.
Подойдёт, если:
- Single-asset structures (one patent или small portfolio) с high projected royalty или sale value
- Semiconductor, deeptech, или non-pharma industries с distributed R&D
- Pre-IPO или pre-acquisition companies wanting clean IP separation
- Patent assertion entities (specialised business model)
- Annual royalty $5M+ или significant capital gains potential
- Multi-jurisdictional R&D без single dominant location
- Long-term horizon (10+ years patent life remaining)
Не подойдёт, если:
- Established pharma/biotech с substantial R&D в single jurisdiction (Switzerland/Ireland лучше)
- Small portfolio (less than 5 patents с royalty stream less than $2M)
- US-derived patents subject to Section 367(d) (limits effectiveness)
- Patents nearing expiration (limited remaining value)
- Standard-essential patents (regulatory complexity)
- Limited budget for substance ($300k+ annually)
Patent structures — это long-term commitment. Patents have 20-year lives. Royalty streams stretch over decades. Substance requirements, regulatory compliance, transfer pricing documentation — все ongoing throughout structure life. Quality counsel critical from very beginning.
Мы участвовали в setup более 25 Cayman patent holdings с 2010 года — для biotechs, semiconductor companies, deeptech startups, и patent assertion entities. Партнёр-юрист с patent expertise проанализирует ваш конкретный case на бесплатной первой встрече и предложит optimal structure (Cayman или альтернативу).